Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
361 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hodgkin Lymphoma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hodgkin Lymphoma - Pipeline Review, H1 2016', provides an overview of the Hodgkin Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma - The report reviews pipeline therapeutics for Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hodgkin Lymphoma therapeutics and enlists all their major and minor projects - The report assesses Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hodgkin Lymphoma Overview 9 Therapeutics Development 10 Pipeline Products for Hodgkin Lymphoma - Overview 10 Pipeline Products for Hodgkin Lymphoma - Comparative Analysis 11 Hodgkin Lymphoma - Therapeutics under Development by Companies 12 Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 16 Hodgkin Lymphoma - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Hodgkin Lymphoma - Products under Development by Companies 20 Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 24 Hodgkin Lymphoma - Companies Involved in Therapeutics Development 25 4SC AG 25 Acetylon Pharmaceuticals, Inc. 26 Actinium Pharmaceuticals, Inc. 27 ADC Therapeutics Sarl 28 Affimed Therapeutics AG 29 Arbutus Biopharma Corporation 30 Bellicum Pharmaceuticals, Inc. 31 Bristol-Myers Squibb Company 32 Celgene Corporation 33 Cell Medica Limited 34 Cellular Biomedicine Group, Inc. 35 Constellation Pharmaceuticals, Inc. 36 Curis, Inc. 37 Faron Pharmaceuticals Oy 38 Fate Therapeutics, Inc. 39 Gamida Cell Ltd. 40 Gilead Sciences, Inc. 41 Incyte Corporation 42 Merck & Co., Inc. 43 Mirati Therapeutics Inc. 44 Molecular Templates Inc. 45 NantKwest, Inc. 46 Novartis AG 47 Ono Pharmaceutical Co., Ltd. 48 Pfizer Inc. 49 Pharmacyclics, Inc. 50 Philogen S.p.A. 51 Rich Pharmaceuticals, Inc. 52 Seattle Genetics, Inc. 53 Selvita S.A. 54 Sigma-Tau S.p.A. 55 Spectrum Pharmaceuticals, Inc. 56 Stemline Therapeutics, Inc. 57 Syndax Pharmaceuticals, Inc. 58 Takeda Pharmaceutical Company Limited 59 TG Therapeutics, Inc. 60 Theravectys SA 61 Trillium Therapeutics Inc. 62 Hodgkin Lymphoma - Therapeutics Assessment 63 Assessment by Monotherapy Products 63 Assessment by Combination Products 64 Assessment by Target 65 Assessment by Mechanism of Action 70 Assessment by Route of Administration 74 Assessment by Molecule Type 76 Drug Profiles 78 (INCB-039110 + INCB-040093) - Drug Profile 78 abexinostat hydrochloride - Drug Profile 79 acalisib - Drug Profile 82 ADCT-301 - Drug Profile 83 AFM-13 - Drug Profile 84 Alocrest - Drug Profile 85 aNK Program - Drug Profile 87 azacitidine - Drug Profile 90 BMS-986016 - Drug Profile 94 BPX-501 - Drug Profile 95 brentuximab vedotin - Drug Profile 97 CBM-C30.1 - Drug Profile 104 Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile 105 Cellular Immunotherapy for Oncology - Drug Profile 106 Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 107 Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile 108 Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 109 Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 110 Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile 111 CMD-003 - Drug Profile 112 CPI-0610 - Drug Profile 114 CUDC-907 - Drug Profile 115 entinostat - Drug Profile 117 Epstein-Barr virus vaccine - Drug Profile 121 Ferritarg - Drug Profile 122 FP-1304 - Drug Profile 123 FT-1050 - Drug Profile 124 haNK Program - Drug Profile 127 INCB-40093 - Drug Profile 129 Indimitecan - Drug Profile 130 Indotecan hydrochloride - Drug Profile 131 Iomab-B - Drug Profile 133 ipilimumab - Drug Profile 135 ixazomib citrate - Drug Profile 140 lirilumab - Drug Profile 144 MK-2206 - Drug Profile 146 mocetinostat - Drug Profile 149 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 152 Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 153 NiCord - Drug Profile 154 nivolumab - Drug Profile 155 NSC-678515 - Drug Profile 163 panobinostat - Drug Profile 164 pembrolizumab - Drug Profile 171 PF-06801591 - Drug Profile 181 PNK-007 - Drug Profile 182 procarbazine hydrochloride - Drug Profile 183 radretumab - Drug Profile 184 Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile 186 resminostat - Drug Profile 187 ricolinostat - Drug Profile 193 RP-323 - Drug Profile 196 ruxolitinib phosphate - Drug Profile 197 SEL-24B489 - Drug Profile 202 SL-101 - Drug Profile 204 SL-501 - Drug Profile 205 temsirolimus - Drug Profile 206 TGR-1202 - Drug Profile 208 TKM-PLK1 - Drug Profile 211 TTI-621 - Drug Profile 213 Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 215 Hodgkin Lymphoma - Recent Pipeline Updates 216 Hodgkin Lymphoma - Dormant Projects 339 Hodgkin Lymphoma - Discontinued Products 342 Hodgkin Lymphoma - Product Development Milestones 343 Featured News & Press Releases 343 Appendix 356 Methodology 356 Coverage 356 Secondary Research 356 Primary Research 356 Expert Panel Validation 356 Contact Us 356 Disclaimer 357
List of Tables Number of Products under Development for Hodgkin Lymphoma, H1 2016 14 Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Development by Companies, H1 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Products under Development by Companies, H1 2016 24 Products under Development by Companies, H1 2016 (Contd..1) 25 Products under Development by Companies, H1 2016 (Contd..2) 26 Products under Development by Companies, H1 2016 (Contd..3) 27 Products under Investigation by Universities/Institutes, H1 2016 28 Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2016 29 Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 30 Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 31 Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016 32 Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016 33 Hodgkin Lymphoma - Pipeline by Arbutus Biopharma Corporation, H1 2016 34 Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 35 Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 36 Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016 37 Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H1 2016 38 Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 39 Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 40 Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2016 41 Hodgkin Lymphoma - Pipeline by Faron Pharmaceuticals Oy, H1 2016 42 Hodgkin Lymphoma - Pipeline by Fate Therapeutics, Inc., H1 2016 43 Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2016 44 Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 45 Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016 46 Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 47 Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016 48 Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2016 49 Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H1 2016 50 Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016 51 Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 52 Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016 53 Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016 54 Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2016 55 Hodgkin Lymphoma - Pipeline by Rich Pharmaceuticals, Inc., H1 2016 56 Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 57 Hodgkin Lymphoma - Pipeline by Selvita S.A., H1 2016 58 Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2016 59 Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 60 Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016 61 Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 62 Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 63 Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 64 Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016 65 Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016 66 Assessment by Monotherapy Products, H1 2016 67 Assessment by Combination Products, H1 2016 68 Number of Products by Stage and Target, H1 2016 70 Number of Products by Stage and Mechanism of Action, H1 2016 75 Number of Products by Stage and Route of Administration, H1 2016 79 Number of Products by Stage and Molecule Type, H1 2016 81 Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 220 Hodgkin Lymphoma - Dormant Projects, H1 2016 343 Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016 344 Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016 345 Hodgkin Lymphoma - Discontinued Products, H1 2016 346
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.